Suvretta Capital Management’s European Biotech Acquisition Corp. Warrant EBACW Stock Holding History

Suvretta Capital Management’s Portfolio EBACW Stock Details EBACW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-100,000	Closed	-$20K	–	109
2022 Q1	$20K	Hold	100,000	–	–	﹤0.01%	85
2021 Q4	$60K	Hold	100,000	–	–	﹤0.01%	92
2021 Q3	$62K	Hold	100,000	–	–	﹤0.01%	103
2021 Q2	$95K	Buy	+100,000	New	+$93K	﹤0.01%	119

Other funds holding EBACW

Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

RCM

Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return

AGC

Angelo Gordon & Co New York $1.06B AUM 47.95% 1-Year Est. Return

Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return

MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return

PMAM

Picton Mahoney Asset Management Toronto, Ontario, Canada $13.5B AUM 50.48% 1-Year Est. Return

ACA

Arena Capital Advisors Los Angeles, California $208M AUM 11.42% 1-Year Est. Return

Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

MCM

Moore Capital Management New York $4.92B AUM 35.41% 1-Year Est. Return

Suvretta Capital Management's EBACW Position: Q2 2022 in Review

Suvretta Capital Management sold out of European Biotech Acquisition Corp. Warrant (EBACW) in Q2 2022, closing a stake of 100,000 shares — an estimated $20K sold.

Suvretta Capital Management first reported a position in EBACW in Q2 2021 and held it in 4 quarters. The position peaked at $95K in Q2 2021. 32 funds tracked by Wall St. Rank hold EBACW as of Q2 2022.

Suvretta Capital Management reported no remaining European Biotech Acquisition Corp. Warrant position as of Q2 2022 after selling out during the quarter.
Suvretta Capital Management sold 100,000 European Biotech Acquisition Corp. Warrant shares in Q2 2022, an estimated $20K.
Suvretta Capital Management first reported a position in European Biotech Acquisition Corp. Warrant in Q2 2021 and held it in 4 quarters.
Suvretta Capital Management's European Biotech Acquisition Corp. Warrant position peaked at $95K in Q2 2021.
32 funds tracked by Wall St. Rank held European Biotech Acquisition Corp. Warrant as of Q2 2022.

Based on Suvretta Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.